Patrick J. Heron, Director at Arcutis Biotherapeutics, Inc. (ARQT), bought 2,520 shares at $13.62 ($34K) on 2025-05-15, disclosed to the SEC on 2025-05-19.
Open-market purchase of $34k ARQT by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Something here stands out, but not much.
| Filing → |
| ARQT | BUY | 2025-06-06 | $30K | — | Filing → |
| ARQT | BUY | 2025-05-23 | $69K | — | Filing → |
| ARQT | BUY | 2025-05-15 | $119K | — | Filing → |